SlideShare a Scribd company logo
Editorial Slides
VP Watch, January 29, 2003, Volume 4, Issue 4
What is the link between infection and cardiovascular events?
 A possible role for infections in
atherosclerosis has been intensely investigated
since the landmark demonstration of herpes
virus-induced atherosclerosis in chickens by
Fabricant in 19781
.
 Human atherosclerotic disease has been
associated with previous exposure to several
microorganisms including Chlamydia
pneumoniae, Porphyromonas gingivalis,
CMV, HSV-1, HSV-2, hepatitis A virus,
influenza virus, enterovirus, etc. Prospective
studies are, however, limited.
A relatively recent approach suggests that the total
pathologic burden is a stronger predictor of
cardiovascular events than any particular
infection2,3,4
.
 Large randomized trials of antibiotic for
secondary prevention of cardiovascular disease
have been performed or are ongoing5,6
but even
failure of those treatments should not be construed
as evidence that the infectious theories are
incorrect.
 As highlighted in VP Watch of this week,
Smieja et al7
, for the Heart Outcomes
Prevention Evaluation (HOPE) study,
analyzed sera from 3168 patients for
antibodies to Chlamydia pneumonia, H.
Pylori, CMV and hepatitis A and followed
the patients over 4.5 years of follow-up.
(Figure 1)
Figure 1 depicts a Kaplan- Meier plot for
cumulative cardiovascular events by titer
levels of C. pneumoniae IgG (A) and IgA(B).
No statistical significance was found.
(Figure 2)
Figure 2 depicts a Kaplan- Meier plot for
cumulative cardiovascular events by
presence or absence of antibody to H. pylori,
CMV, and HAV. Serology for CMV shows a
mild predictive correlation with
cardiovascular events with a hazard ratio
(HR) of 1.24.
(Figure 3)
 Figure 3 depicts a Kaplan-Meier plot for
cumulative cardiovascular events by total
pathogen score (C pneumoniae IgG 512 or
IgA 64; H pylori >40 AU; CMV >0.4
mIU/mL; and HAV >20 IU/mL). HR
compares total pathogen score of 4 versus 0
or 1 combined. A score of 4 had an
adjusted HR of 1.41 versus 0 or 1.
 Exposure to CMV but not C. pneumoniae,
H. pylori or HAV was associated with a
slight excess risk of subsequent
cardiovascular events (myocardial
infarction, stroke, cardiovascular death)
Conclusion
 Total pathogen score based on these 4
infections predicted an increase hazard of
cardiovascular events compared to the
presence of none or only one of these
infections.
Con’t
ReferencesReferences
1. Fabricant CG, Fabricant J, Litrenta MM, et al. Virus-
induced atherosclerosis. J Exp Med. 1978; 148: 335–340.
2. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of
pathogen burden and risk of myocardial infarction or
death. Circulation. 2001; 103: 45–51.
3. Zhu J, Quyyumi AA, Norman JE, et al. Effects of total
pathogen burden on coronary artery disease risk and C-
reactive protein levels. Am J Cardiol. 2000; 85: 140–146
4. Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of
viral and bacterial infectious burden on long-term
prognosis in patients with coronary artery disease.
Circulation. 2001; 104: 25–31.
References
5. Dunne MW. Rationale, and design of a secondary
prevention trial of antibiotic use in patients after
myocardial infarction: the WIZARD (Weekly Intervention
with Zithromax [Azithromycin] for Atherosclerosis and Its
Related Disorders) Trial. J Infect Dis. 2000; 181 (suppl 3):
S572–S578.
6. Jackson LA. Description and status of the Azithromycin
and Coronary Events Study (ACES). J Infect Dis. 2000;
181 (suppl 3): S579–S581.
7. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi
Q, Dzavik V, McQueen M, Yusuf S. Heart Outcomes
Prevention Evaluation (HOPE) Study Investigators.
Circulation 2003;107:251-7

More Related Content

What's hot

Cortis in cap2
Cortis in cap2Cortis in cap2
Cortis in cap2
Manto Liapikou
 
Ophthalmic changes amongst PLWHA_eposter
Ophthalmic changes amongst PLWHA_eposterOphthalmic changes amongst PLWHA_eposter
Ophthalmic changes amongst PLWHA_eposter
Vaibhavi Noticewala
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
Ramachandra Barik
 
Managing comorbidities in heart failure
Managing comorbidities in heart failureManaging comorbidities in heart failure
Managing comorbidities in heart failure
ashwani mehta
 
Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever
ijac journal
 
S12981 015-0078-3
S12981 015-0078-3S12981 015-0078-3
S12981 015-0078-3
Adiel Ojeda
 
Risk of heart failure after community acquired pneumonia: prospective control...
Risk of heart failure after community acquired pneumonia: prospective control...Risk of heart failure after community acquired pneumonia: prospective control...
Risk of heart failure after community acquired pneumonia: prospective control...
Bhargav Kiran
 
Covid 19 and cardiovascular system
Covid 19 and cardiovascular systemCovid 19 and cardiovascular system
Covid 19 and cardiovascular system
gisa_legal
 
9 x fr severo en covid china
9 x fr severo en covid china9 x fr severo en covid china
9 x fr severo en covid china
Freddy Flores Malpartida
 
Covid-19 :Cardiovascular considerations
Covid-19 :Cardiovascular considerationsCovid-19 :Cardiovascular considerations
Covid-19 :Cardiovascular considerations
Dr.Mahmoud Abbas
 
Jarrett2017
Jarrett2017Jarrett2017
Jarrett2017
Adiel Ojeda
 
Nature ei
Nature   eiNature   ei
Nature ei
gisa_legal
 
Sepsis rev
Sepsis revSepsis rev
Sepsis rev
murfam
 
1933 088x-15.3.138
1933 088x-15.3.1381933 088x-15.3.138
1933 088x-15.3.138
Adiel Ojeda
 
COVID-19 & Diabetes by Dr Shahjada Selim
COVID-19 & Diabetes by Dr Shahjada SelimCOVID-19 & Diabetes by Dr Shahjada Selim
COVID-19 & Diabetes by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...
Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...
Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...
asclepiuspdfs
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
Heba Essam
 
Central Nervous System Histoplasmosis Related to Bioprosthetic Endocarditis
Central Nervous System Histoplasmosis Related to Bioprosthetic EndocarditisCentral Nervous System Histoplasmosis Related to Bioprosthetic Endocarditis
Central Nervous System Histoplasmosis Related to Bioprosthetic Endocarditis
asclepiuspdfs
 

What's hot (18)

Cortis in cap2
Cortis in cap2Cortis in cap2
Cortis in cap2
 
Ophthalmic changes amongst PLWHA_eposter
Ophthalmic changes amongst PLWHA_eposterOphthalmic changes amongst PLWHA_eposter
Ophthalmic changes amongst PLWHA_eposter
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
Managing comorbidities in heart failure
Managing comorbidities in heart failureManaging comorbidities in heart failure
Managing comorbidities in heart failure
 
Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever Low Platelet Count Associated With Dengue Hemorrhagic Fever
Low Platelet Count Associated With Dengue Hemorrhagic Fever
 
S12981 015-0078-3
S12981 015-0078-3S12981 015-0078-3
S12981 015-0078-3
 
Risk of heart failure after community acquired pneumonia: prospective control...
Risk of heart failure after community acquired pneumonia: prospective control...Risk of heart failure after community acquired pneumonia: prospective control...
Risk of heart failure after community acquired pneumonia: prospective control...
 
Covid 19 and cardiovascular system
Covid 19 and cardiovascular systemCovid 19 and cardiovascular system
Covid 19 and cardiovascular system
 
9 x fr severo en covid china
9 x fr severo en covid china9 x fr severo en covid china
9 x fr severo en covid china
 
Covid-19 :Cardiovascular considerations
Covid-19 :Cardiovascular considerationsCovid-19 :Cardiovascular considerations
Covid-19 :Cardiovascular considerations
 
Jarrett2017
Jarrett2017Jarrett2017
Jarrett2017
 
Nature ei
Nature   eiNature   ei
Nature ei
 
Sepsis rev
Sepsis revSepsis rev
Sepsis rev
 
1933 088x-15.3.138
1933 088x-15.3.1381933 088x-15.3.138
1933 088x-15.3.138
 
COVID-19 & Diabetes by Dr Shahjada Selim
COVID-19 & Diabetes by Dr Shahjada SelimCOVID-19 & Diabetes by Dr Shahjada Selim
COVID-19 & Diabetes by Dr Shahjada Selim
 
Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...
Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...
Dengue Fever-Related Cardiac manifestation in Ibn-Sina Hospital Mukalla, Hadh...
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Central Nervous System Histoplasmosis Related to Bioprosthetic Endocarditis
Central Nervous System Histoplasmosis Related to Bioprosthetic EndocarditisCentral Nervous System Histoplasmosis Related to Bioprosthetic Endocarditis
Central Nervous System Histoplasmosis Related to Bioprosthetic Endocarditis
 

Viewers also liked

Dr.jang@aha2002
Dr.jang@aha2002Dr.jang@aha2002
Dr falk's slides part ii
Dr falk's slides  part iiDr falk's slides  part ii
Old vulnerable patient slides without movies
Old vulnerable patient slides without moviesOld vulnerable patient slides without movies
Old vulnerable patient slides without movies
Society for Heart Attack Prevention and Eradication
 
223 edta chelating therapy
223 edta chelating therapy223 edta chelating therapy
Esv2n22
Esv2n22Esv2n22
Macrophage induced proteolysis zorina galis- emory u
Macrophage induced proteolysis  zorina galis- emory uMacrophage induced proteolysis  zorina galis- emory u
Macrophage induced proteolysis zorina galis- emory u
Society for Heart Attack Prevention and Eradication
 
Erbel
ErbelErbel
Asme05 ibis
Asme05 ibisAsme05 ibis
505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...
Society for Heart Attack Prevention and Eradication
 
Out of hospital 2
Out of hospital 2Out of hospital 2
Pandemic of cvd atlanta
Pandemic of cvd atlantaPandemic of cvd atlanta
Ebt rumberger- ohio state u- part 4
Ebt   rumberger- ohio state u-  part 4Ebt   rumberger- ohio state u-  part 4
Ebt rumberger- ohio state u- part 4
Society for Heart Attack Prevention and Eradication
 
Dr maseri aeha_neworleans_mar2004
Dr maseri aeha_neworleans_mar2004Dr maseri aeha_neworleans_mar2004
Dr maseri aeha_neworleans_mar2004
Society for Heart Attack Prevention and Eradication
 
Esv2n15
Esv2n15Esv2n15
Litovsky1
Litovsky1Litovsky1
Percutaneous coronary intervention by hossein
Percutaneous coronary intervention  by hosseinPercutaneous coronary intervention  by hossein
Percutaneous coronary intervention by hossein
Society for Heart Attack Prevention and Eradication
 
Contrast enhanced mri of vulnerable plaque black or white
Contrast enhanced mri of vulnerable plaque black or whiteContrast enhanced mri of vulnerable plaque black or white
Contrast enhanced mri of vulnerable plaque black or white
Society for Heart Attack Prevention and Eradication
 
Ebt and coronary artery calcium
Ebt and coronary artery calciumEbt and coronary artery calcium

Viewers also liked (18)

Dr.jang@aha2002
Dr.jang@aha2002Dr.jang@aha2002
Dr.jang@aha2002
 
Dr falk's slides part ii
Dr falk's slides  part iiDr falk's slides  part ii
Dr falk's slides part ii
 
Old vulnerable patient slides without movies
Old vulnerable patient slides without moviesOld vulnerable patient slides without movies
Old vulnerable patient slides without movies
 
223 edta chelating therapy
223 edta chelating therapy223 edta chelating therapy
223 edta chelating therapy
 
Esv2n22
Esv2n22Esv2n22
Esv2n22
 
Macrophage induced proteolysis zorina galis- emory u
Macrophage induced proteolysis  zorina galis- emory uMacrophage induced proteolysis  zorina galis- emory u
Macrophage induced proteolysis zorina galis- emory u
 
Erbel
ErbelErbel
Erbel
 
Asme05 ibis
Asme05 ibisAsme05 ibis
Asme05 ibis
 
505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...505 definitions of arterial remodeling in post mortem and intravascular ultra...
505 definitions of arterial remodeling in post mortem and intravascular ultra...
 
Out of hospital 2
Out of hospital 2Out of hospital 2
Out of hospital 2
 
Pandemic of cvd atlanta
Pandemic of cvd atlantaPandemic of cvd atlanta
Pandemic of cvd atlanta
 
Ebt rumberger- ohio state u- part 4
Ebt   rumberger- ohio state u-  part 4Ebt   rumberger- ohio state u-  part 4
Ebt rumberger- ohio state u- part 4
 
Dr maseri aeha_neworleans_mar2004
Dr maseri aeha_neworleans_mar2004Dr maseri aeha_neworleans_mar2004
Dr maseri aeha_neworleans_mar2004
 
Esv2n15
Esv2n15Esv2n15
Esv2n15
 
Litovsky1
Litovsky1Litovsky1
Litovsky1
 
Percutaneous coronary intervention by hossein
Percutaneous coronary intervention  by hosseinPercutaneous coronary intervention  by hossein
Percutaneous coronary intervention by hossein
 
Contrast enhanced mri of vulnerable plaque black or white
Contrast enhanced mri of vulnerable plaque black or whiteContrast enhanced mri of vulnerable plaque black or white
Contrast enhanced mri of vulnerable plaque black or white
 
Ebt and coronary artery calcium
Ebt and coronary artery calciumEbt and coronary artery calcium
Ebt and coronary artery calcium
 

Similar to 506 what is the link between infection and cardiovascular events

Rheumatic feve 2018
Rheumatic feve  2018Rheumatic feve  2018
Rheumatic feve 2018
rajasthan govt
 
Cell Salvage in PBM
Cell Salvage in PBMCell Salvage in PBM
Cell Salvage in PBM
Testa Emanuela
 
A fresh look at cell salvage
A fresh look at cell salvageA fresh look at cell salvage
A fresh look at cell salvage
anemo_site
 
Mathematical modeling
Mathematical modelingMathematical modeling
Mathematical modeling
miguelhowella
 
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015
Hivlife Info
 
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...
hivlifeinfo
 
HCV in CKD
HCV in CKDHCV in CKD
HCV in CKD
Pratap Tiwari
 
Medical.edited
Medical.editedMedical.edited
Medical.edited
Godfrey Arap Kangogo
 
Global Burden Of Hypertension In People Living With HIV.docx
Global Burden Of Hypertension In People Living With HIV.docxGlobal Burden Of Hypertension In People Living With HIV.docx
Global Burden Of Hypertension In People Living With HIV.docx
4934bk
 
Rheumatic feve 2018
Rheumatic feve  2018Rheumatic feve  2018
Rheumatic feve 2018
rajasthan govt
 
Riesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIHRiesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIH
Medint81
 
RA-ILD Infection Poster ACR 2016 (Final Version)
RA-ILD Infection Poster ACR 2016 (Final Version)RA-ILD Infection Poster ACR 2016 (Final Version)
RA-ILD Infection Poster ACR 2016 (Final Version)
J.A. Zamora-Legoff
 
2015-42-4_6
2015-42-4_62015-42-4_6
2015-42-4_6
Mai Nguyen Thi Ngoc
 
HCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploaded
HCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploadedHCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploaded
HCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploaded
Pratap Tiwari
 
Antibiotics bugs- us1
Antibiotics bugs- us1 Antibiotics bugs- us1
Antibiotics bugs- us1
Reham Ragab
 
Antibiotics bugs- us1 [autosaved]
Antibiotics bugs- us1 [autosaved]Antibiotics bugs- us1 [autosaved]
Antibiotics bugs- us1 [autosaved]
khaledalazzazy1
 
Hiv associted dvt
Hiv associted dvtHiv associted dvt
Hiv associted dvt
Keshri Yadav
 
Journal of Hepatitis Research
Journal of Hepatitis ResearchJournal of Hepatitis Research
Journal of Hepatitis Research
Austin Publishing Group
 
Journal of Hepatitis Research
Journal of Hepatitis ResearchJournal of Hepatitis Research
Journal of Hepatitis Research
Austin Publishing Group
 
Jamainternal Internal Medicine
Jamainternal Internal MedicineJamainternal Internal Medicine
Jamainternal Internal Medicine
Valentina Corona
 

Similar to 506 what is the link between infection and cardiovascular events (20)

Rheumatic feve 2018
Rheumatic feve  2018Rheumatic feve  2018
Rheumatic feve 2018
 
Cell Salvage in PBM
Cell Salvage in PBMCell Salvage in PBM
Cell Salvage in PBM
 
A fresh look at cell salvage
A fresh look at cell salvageA fresh look at cell salvage
A fresh look at cell salvage
 
Mathematical modeling
Mathematical modelingMathematical modeling
Mathematical modeling
 
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015
Cardiovascular Disease in HIV-Infected Patients.Predict It and Prevent It.2015
 
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...
Сердечно-сосудистые заболевания у ВИЧ-инфицированных пациентов : предсказать ...
 
HCV in CKD
HCV in CKDHCV in CKD
HCV in CKD
 
Medical.edited
Medical.editedMedical.edited
Medical.edited
 
Global Burden Of Hypertension In People Living With HIV.docx
Global Burden Of Hypertension In People Living With HIV.docxGlobal Burden Of Hypertension In People Living With HIV.docx
Global Burden Of Hypertension In People Living With HIV.docx
 
Rheumatic feve 2018
Rheumatic feve  2018Rheumatic feve  2018
Rheumatic feve 2018
 
Riesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIHRiesgo Cardiovascular en el paciente VIH
Riesgo Cardiovascular en el paciente VIH
 
RA-ILD Infection Poster ACR 2016 (Final Version)
RA-ILD Infection Poster ACR 2016 (Final Version)RA-ILD Infection Poster ACR 2016 (Final Version)
RA-ILD Infection Poster ACR 2016 (Final Version)
 
2015-42-4_6
2015-42-4_62015-42-4_6
2015-42-4_6
 
HCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploaded
HCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploadedHCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploaded
HCV MANAGEMENT IN PATIENT WITH KIDNEY DISEASE..reuploaded
 
Antibiotics bugs- us1
Antibiotics bugs- us1 Antibiotics bugs- us1
Antibiotics bugs- us1
 
Antibiotics bugs- us1 [autosaved]
Antibiotics bugs- us1 [autosaved]Antibiotics bugs- us1 [autosaved]
Antibiotics bugs- us1 [autosaved]
 
Hiv associted dvt
Hiv associted dvtHiv associted dvt
Hiv associted dvt
 
Journal of Hepatitis Research
Journal of Hepatitis ResearchJournal of Hepatitis Research
Journal of Hepatitis Research
 
Journal of Hepatitis Research
Journal of Hepatitis ResearchJournal of Hepatitis Research
Journal of Hepatitis Research
 
Jamainternal Internal Medicine
Jamainternal Internal MedicineJamainternal Internal Medicine
Jamainternal Internal Medicine
 

More from Society for Heart Attack Prevention and Eradication

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
Society for Heart Attack Prevention and Eradication
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
Society for Heart Attack Prevention and Eradication
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
Society for Heart Attack Prevention and Eradication
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
Society for Heart Attack Prevention and Eradication
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
Society for Heart Attack Prevention and Eradication
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
Society for Heart Attack Prevention and Eradication
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
Society for Heart Attack Prevention and Eradication
 
Vp watch2002
Vp watch2002Vp watch2002
Vp symposium31602
Vp symposium31602Vp symposium31602
Vpschoenhagen
VpschoenhagenVpschoenhagen

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 

506 what is the link between infection and cardiovascular events

  • 1. Editorial Slides VP Watch, January 29, 2003, Volume 4, Issue 4 What is the link between infection and cardiovascular events?
  • 2.  A possible role for infections in atherosclerosis has been intensely investigated since the landmark demonstration of herpes virus-induced atherosclerosis in chickens by Fabricant in 19781 .
  • 3.  Human atherosclerotic disease has been associated with previous exposure to several microorganisms including Chlamydia pneumoniae, Porphyromonas gingivalis, CMV, HSV-1, HSV-2, hepatitis A virus, influenza virus, enterovirus, etc. Prospective studies are, however, limited.
  • 4. A relatively recent approach suggests that the total pathologic burden is a stronger predictor of cardiovascular events than any particular infection2,3,4 .  Large randomized trials of antibiotic for secondary prevention of cardiovascular disease have been performed or are ongoing5,6 but even failure of those treatments should not be construed as evidence that the infectious theories are incorrect.
  • 5.  As highlighted in VP Watch of this week, Smieja et al7 , for the Heart Outcomes Prevention Evaluation (HOPE) study, analyzed sera from 3168 patients for antibodies to Chlamydia pneumonia, H. Pylori, CMV and hepatitis A and followed the patients over 4.5 years of follow-up.
  • 7. Figure 1 depicts a Kaplan- Meier plot for cumulative cardiovascular events by titer levels of C. pneumoniae IgG (A) and IgA(B). No statistical significance was found.
  • 9. Figure 2 depicts a Kaplan- Meier plot for cumulative cardiovascular events by presence or absence of antibody to H. pylori, CMV, and HAV. Serology for CMV shows a mild predictive correlation with cardiovascular events with a hazard ratio (HR) of 1.24.
  • 11.  Figure 3 depicts a Kaplan-Meier plot for cumulative cardiovascular events by total pathogen score (C pneumoniae IgG 512 or IgA 64; H pylori >40 AU; CMV >0.4 mIU/mL; and HAV >20 IU/mL). HR compares total pathogen score of 4 versus 0 or 1 combined. A score of 4 had an adjusted HR of 1.41 versus 0 or 1.
  • 12.  Exposure to CMV but not C. pneumoniae, H. pylori or HAV was associated with a slight excess risk of subsequent cardiovascular events (myocardial infarction, stroke, cardiovascular death) Conclusion
  • 13.  Total pathogen score based on these 4 infections predicted an increase hazard of cardiovascular events compared to the presence of none or only one of these infections. Con’t
  • 14. ReferencesReferences 1. Fabricant CG, Fabricant J, Litrenta MM, et al. Virus- induced atherosclerosis. J Exp Med. 1978; 148: 335–340. 2. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation. 2001; 103: 45–51. 3. Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C- reactive protein levels. Am J Cardiol. 2000; 85: 140–146 4. Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001; 104: 25–31.
  • 15. References 5. Dunne MW. Rationale, and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (Weekly Intervention with Zithromax [Azithromycin] for Atherosclerosis and Its Related Disorders) Trial. J Infect Dis. 2000; 181 (suppl 3): S572–S578. 6. Jackson LA. Description and status of the Azithromycin and Coronary Events Study (ACES). J Infect Dis. 2000; 181 (suppl 3): S579–S581. 7. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Circulation 2003;107:251-7